Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.
about
Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathwaysHIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaquesNeuroprotection for stroke: current status and future perspectivesMolecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseasesChick embryo partial ischemia model: a new approach to study ischemia ex vivoHypoxia--implications for pharmaceutical developmentsSynergistic effect of HIF-1alpha gene therapy and HIF-1-activated bone marrow-derived angiogenic cells in a mouse model of limb ischemia.Gene expression profile of rat left ventricles reveals persisting changes following chronic mild exercise protocol: implications for cardioprotection.Effect of proline analogues on activity of human prolyl hydroxylase and the regulation of HIF signal transduction pathway.Novel multi-modal strategies to promote brain and spinal cord injury recovery.Differential evolutionary rates of neuronal transcriptome in Aplysia kurodai and Aplysia californica as a tool for gene mining.OGFOD1, a member of the 2-oxoglutarate and iron dependent dioxygenase family, functions in ischemic signaling.HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.Impaired expression of neuroprotective molecules in the HIF-1alpha pathway following traumatic brain injury in aged mice.Impaired Ca(2+)-handling in HIF-1alpha(+/-) mice as a consequence of pressure overload.Relative Contribution of Prolyl Hydroxylase-Dependent and -Independent Degradation of HIF-1alpha by Proteasomal Pathways in Cerebral Ischemia.The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's diseaseEndothelial progenitor cells transplantation attenuated blood-brain barrier damage after ischemia in diabetic mice via HIF-1α.Desferrioxamine regulates HIF-1 alpha expression in neonatal rat brain after hypoxia-ischemiaSmall molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injuryInhibition of prolyl hydroxylases by dimethyloxaloylglycine after stroke reduces ischemic brain injury and requires hypoxia inducible factor-1α.Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and blood-brain barrier damage in a rat model of ischemic strokeEvidence for a therapeutic effect of Braintone on ischemic brain damageAdvances in iron chelation: an update.Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.Roles of individual prolyl-4-hydroxylase isoforms in the first 24 hours following transient focal cerebral ischaemia: insights from genetically modified mice.Mechanisms of mycotoxin-induced neurotoxicity through oxidative stress-associated pathways.Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseasesNitric oxide prevents axonal degeneration by inducing HIF-1-dependent expression of erythropoietin.Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.Cell type-specific dependency on the PI3K/Akt signaling pathway for the endogenous Epo and VEGF induction by baicalein in neurons versus astrocytes.Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitusProphylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis.Hypoxia inducible factor-1alpha mediates protection of DL-3-n-butylphthalide in brain microvascular endothelial cells against oxygen glucose deprivation-induced injury.Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice.Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.Erythropoietin in brain development and beyond.Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?
P2860
Q24312134-88B4505B-F181-4F05-B79B-50182B7DF43EQ24684076-50E9A7F3-CCE1-454D-A930-54F1643A17EDQ26853031-6B5A103E-59E3-46E7-BBC3-E759DF104EF8Q28297656-A2012830-9A0D-4529-A54B-41622606C63CQ28473867-39130DF3-FA6E-4C3B-9D86-391306C0085BQ28741565-7C60B268-7D4B-4DC6-9736-9B1E3AC3B4DFQ30492111-3E8E4F1F-8913-4006-A660-CA5F71E2A0A9Q30495607-E4D0E6FF-A702-4674-8F08-2C68798C3807Q31159179-6C074AA1-41B0-40B4-B76C-519755FFAD6BQ33390906-4634C5D1-7B9C-48F6-86F7-31D6CB78612AQ33600033-BF59D75A-7F95-4B9F-9C50-BBF62EC9ECE2Q33616970-1DBC5F0D-C3E5-444C-B456-DE6FB9CC9833Q33649916-91B12F7A-4D78-4773-8B56-7459A7D8DF4CQ33657749-2ADF7308-C2D1-4A71-8CC9-4CE3774E8D50Q33684981-E81BF921-71D3-46A5-AD57-75163A668A23Q33696477-D19309AB-9323-45AD-B1FD-7C5082A71E10Q33850971-5461CC8B-D5F5-4C19-A318-8220592C3789Q33893649-678056E9-EF40-4B12-B956-791DB1B323B8Q33961956-A7A4B3AA-BEB8-4335-BAF0-7C66B74F1139Q34066937-9C12B2D1-5BDC-433F-B1A1-5476B18657CCQ34068989-D1C915D6-3E3B-40E9-B040-35AE1CDF816CQ34081831-C49E1857-E1F6-4F9C-9E6A-03C2C4800565Q34094726-41C79AFA-C145-4793-AED6-69114418874EQ34174307-94F47B5A-B3A1-4229-BE53-F38DAEAA8C3CQ34271664-93B92BC6-4973-409F-9D36-01FADF322B58Q34276898-37F9784C-C0EF-451F-A483-810B17F739E7Q34632669-5EC731B3-5C1B-4F9A-A804-EC3AFDF006BDQ34657382-FD2495F7-1E20-4F2D-9D1E-9399BFE27B84Q34720972-596A0145-F04A-43F8-8E89-B24BF02B5BA1Q34802673-A3348AC7-85CD-4972-ABED-944293B82FDCQ34886522-F5C197D4-F131-4C88-AB16-000F2A9FC624Q34914164-49620AB5-86E6-4C63-BB8A-7ECF85F1E7D9Q35088183-37D96CD2-D385-4851-BA26-23D4FA3A4B46Q35101307-F6F89998-D59D-41F9-82E0-ECF9824571EBQ35123810-F388071E-C0A3-4B1C-8EF9-55B607BD477EQ35173596-9E9452E1-9246-49A2-9475-745C58EC5616Q35711431-E116DF82-D684-449B-A382-DF78A3C55A0FQ35870320-A25DD0CD-63B3-42A0-9B37-1966AAA94A80Q35909929-A78DE8D2-47D7-4A5D-AF2F-F62233590501Q36079321-9462A44F-3845-4AE7-91A5-650D65CF6D92
P2860
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Hypoxia-inducible factor proly ...... in the central nervous system.
@en
type
label
Hypoxia-inducible factor proly ...... in the central nervous system.
@en
prefLabel
Hypoxia-inducible factor proly ...... in the central nervous system.
@en
P2093
P2860
P50
P356
P1476
Hypoxia-inducible factor proly ...... in the central nervous system.
@en
P2093
Ambreena Siddiq
Ingrid Langsetmo
Issam A Ayoub
James R Connor
Juan C Chavez
Leila Aminova
Rajiv R Ratan
Robert A Cherny
Sapan Shah
Stephanie M Patton
P2860
P304
41732-41743
P356
10.1074/JBC.M504963200
P407
P577
2005-10-13T00:00:00Z